Keith Kohl of Angel Publishing’s Topline Trader is promoting “AI Doctor,” a pitch built around an AI drug-discovery biotech. The filings support the company match, but not several of the ad’s biggest claims.
One promotion, several names — all of them point to the same pitch, and the same stock.
“World Stunned as ‘AI Doctor’ Produces Cures at Light Speed — Now Bill Gates, BlackRock, and Citigroup Are ALL Loading up on This Tiny $5 AI Biotech Stock” is the headline from Keith Kohl of Angel Publishing’s Topline Trader.
The promotion promises an AI drug-discovery breakthrough: faster research, dramatically lower costs, an alleged first-ever AI drug entering human trials, and a parade of famous investors supposedly buying in. The offer is available today, with spots limited to 30 new members.
The stock is Recursion Pharmaceuticals, ticker RXRX. The identification is highly confident at 92 out of 100, even though several of the promotion’s loudest details don’t survive a look at the filings.
The useful fingerprints are unusually specific: a Salt Lake City biotech, an AI drug-discovery platform, a collaboration with NVIDIA, the BioHive-2 supercomputer, and REC-994, a machine-learning-discovered drug that entered human trials. Add relationships with Bayer, Roche and Merck KGaA, and the search narrows quickly.
The same pitch also wears several costumes: “Golden Age of AI Cures,” “Quantum Quake,” “The BIGGEST Boom American Medicine has EVER SEEN,” “The Golden Age of AI Cures,” “The First AI Drug in History,” and “TOP BIOTECH STOCK STORY of the year.” They’re different labels for the same AI-drug-development story.
The company is Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), headquartered in Salt Lake City, Utah. Its 2025 Form 10-K describes a clinical-stage TechBio company built around the Recursion OS, which combines biological, chemical and computational technologies to industrialize drug discovery.
The strongest fingerprint is BioHive-2. NVIDIA’s official account places the system at Recursion’s Salt Lake City headquarters, while Recursion and a Fortune account republished by the company describe NVIDIA and Recursion employees spending three weeks building it. Recursion called BioHive-2 the largest supercomputer in the pharmaceutical industry. The other major clue is REC-994: Recursion announced FDA IND clearance in 2017 for the machine-learning-discovered asset to enter a Phase 1 human trial.
The partner list reinforces the match. Recursion’s filings and company materials identify collaborations with Bayer, Roche and Genentech, and Merck KGaA. The match isn’t perfect: the sources don’t show a current Bristol Myers Squibb collaboration, and they don’t establish Bill Gates personally buying shares. Those are problems with the promotion’s wording, not with the RXRX identification.
The claim-by-claim checks separate Recursion’s documented technology and partnerships from the promotional upgrades layered on top. The filings, company announcements, NVIDIA materials, FDA history, investor presentations and institutional ownership disclosures tell a much less cinematic story, but a more useful one.
That distinction matters here. A real AI platform, a real supercomputer and a real clinical program can still be wrapped in claims that stretch speed, cost savings, novelty and investor activity beyond what the sources support.
| The promotion claims | Verdict | What we found |
|---|---|---|
| The stock is around $5 a share. | Overstated | RXRX traded at about $3.20 on August 5, 2026, which is below but materially away from $5. |
| The stock trades well under $10 a share. | Checks out | RXRX traded at about $3.20 on August 5, 2026, according to market data. |
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The promotion says the offer is available today and limited to 30 new members. We received it on only one day, August 3, 2026, so the record is too thin to say whether that deadline rolls.
Nothing in the promotion ties the deadline to a checkable event such as an earnings date, FDA decision or index change. For now, all we can say is that “today” was announced once, and there isn’t enough history to judge what happens next.
The pitch’s central claim is simple: AI can make drug discovery faster and cheaper, Recursion has already put an AI-discovered drug into human trials, and major investors are loading up before everyone else notices. The first two links have real support. The last one is where the sales copy starts wobbling.
Recursion’s public FAQ says its platform can reach speeds of up to three times traditional industry averages, not ten times faster. Its investor presentation showed an approximately 77.5% reduction in cost to IND, from $80 million to $18 million, not an 80% reduction across overall drug development. REC-994 may be an early AI-discovered clinical asset, but NCATS describes it as one of the first such drugs, not definitively the first in history. The ad takes three credible ideas and turns each dial past the mark.
On its own merits, Recursion is a real clinical-stage biotech with a genuine computational drug-discovery platform, multiple programs, a documented NVIDIA collaboration and relationships with major pharmaceutical companies. That makes it interesting. It doesn’t make “produces cures at light speed” a fact, and entering human trials is a beginning, not proof of a cure.
Would I treat RXRX as an automatic buy because Bill Gates, BlackRock and Citigroup supposedly see the future? No. BlackRock’s disclosed position supports institutional interest, but the filings don’t establish the sweeping accumulation story for every name in the headline; NVIDIA’s investment was historical, and Vanguard and SoftBank disclosures don’t show the claimed recent buying. The stock identification is strong. The argument selling it is much less so.
How confident are we? 92 out of 100. We identified Recursion Pharmaceuticals Inc (RXRX) from the promotion's own clues and checked 27 of its claims against filings, earnings calls, ownership records, market data and public reporting. This is our analysis, not the publisher's disclosure — we have no relationship with them.
Knowing which stock it is only gets you halfway. We score RXRX on valuation, profitability, growth, financial health and momentum — and reach our own conclusion, independent of how it was sold to you.
See the RXRX data →Independent of the promotion — our own numbers, score and analysis.
Everything we track on RXRX in one place — the TickerSpark Score, price charts, key financials, and our latest coverage.
| The company is a tiny biotech stock. | Checks out | Recursion's corporate filings describe it as a clinical-stage biotechnology company, and its market capitalization was approximately $1.7 billion. |
| The company is an AI-powered drug-discovery biotech. | Checks out | Recursion's 2025 Form 10-K describes the company as a TechBio business using the Recursion OS to industrialize drug discovery with biological, chemical, and computational technologies. |
| The BioHive-2 build took place at a Salt Lake City mall. | Overstated | Recursion's filings describe 41 South Rio Grande Street as office, research, and laboratory space, while Fortune's account places the three-week sprint in a data center; the Gateway mall-area connection does not establish a literal mall build. |
| The company is headquartered in Salt Lake City, Utah. | Checks out | Recursion's 2025 Form 10-K and corporate information identify Salt Lake City, Utah, as the company's headquarters. |
| Recursion and NVIDIA employees worked together to build BioHive-2. | Checks out | NVIDIA's official blog says BioHive-2 is located at Recursion's Salt Lake City headquarters, and Recursion described the system as built in collaboration with NVIDIA. |
| Recursion and NVIDIA employees spent three weeks building BioHive-2. | Checks out | A Fortune account republished by Recursion says NVIDIA and Recursion employees spent three weeks in Salt Lake City building BioHive-2. |
| BioHive-2 is the largest supercomputer in the pharmaceutical industry. | Checks out | Recursion's May 2024 announcement described BioHive-2 as the largest supercomputer in the pharmaceutical industry. |
| BioHive-2 is the fastest supercomputer in the industry. | Can't verify | Recursion and NVIDIA materials establish BioHive-2's scale and ranking, but the cited sources do not establish that it was the fastest supercomputer in the industry. |
| The system finds potential new drugs up to 10 times faster than conventional discovery. | Overstated | Recursion's public FAQ states speeds of up to three times traditional industry averages, not ten times faster, although its platform is genuinely designed to accelerate drug discovery. |
| The system reduces development costs by up to 80%. | Overstated | Recursion's November 2024 investor presentation showed an approximately 77.5% reduction in cost to IND, from $80 million to $18 million, rather than an 80% reduction across overall drug development costs. |
| The company has an AI-discovered drug that entered human clinical trials. | Checks out | Recursion announced FDA IND clearance for REC-994 in September 2017 and said the machine-learning-discovered asset would enter a Phase 1 human trial. |
| The company is currently on track to have the first-ever AI drug enter human trials. | Overstated | Recursion describes REC-994 as its first clinical program discovered with an early machine-learning system, while NCATS calls it one of the first such drugs rather than the industry's first ever. |
| The company has many other drugs filling its pipeline. | Checks out | Recursion's latest corporate disclosures describe multiple additional clinical and preclinical programs beyond REC-994. |
| The company has a partnership with Bayer. | Checks out | Bayer and Recursion announced a drug-discovery collaboration in 2020 and later expanded its focus to precision oncology. |
| The company has a partnership with Roche. | Checks out | Recursion's 2025 Form 10-K and company partner materials identify Roche and Genentech as strategic collaboration partners. |
| The company has a partnership with Bristol-Myers Squibb. | Contradicted | Recursion's 2025 Form 10-K identifies Roche/Genentech, Sanofi, Bayer, Merck KGaA, and other counterparties but does not disclose a current Bristol Myers Squibb collaboration. |
| The company has a partnership with Merck KGaA. | Checks out | Recursion's 2025 Form 10-K describes a September 2023 research collaboration agreement with Merck KGaA, including upfront and potential milestone payments. |
| Bill Gates is quietly scooping up shares of the company. | Can't verify | Recursion's partner materials and filings document a Bill & Melinda Gates Foundation relationship, but no source reviewed documents Bill Gates personally buying RXRX shares. |
| BlackRock is quietly scooping up shares of the company. | Checks out | BlackRock's latest disclosed institutional position was approximately 43.2 million RXRX shares, with the reported position up about 11.1%. |
| Citigroup is quietly scooping up shares of the company. | Can't verify | Recursion's filings identify Citigroup Global Markets as an ATM sales-agent bank, but the sources reviewed do not establish that Citigroup was accumulating RXRX for its own account. |
| NVIDIA is quietly scooping up shares of the company. | Overstated | Recursion announced a $50 million NVIDIA investment in July 2023 for 7,706,363 shares, but the record supports a historical strategic investment rather than ongoing quiet accumulation. |
| Vanguard is quietly scooping up shares of the company. | Overstated | Vanguard's latest ownership disclosures show approximately 47.2 million RXRX shares, but the reported positions show no recent increase supporting the claim that it was scooping up shares. |
Cancel anytime
Michael A. Robinson’s Weiss Ratings pitch, sold through Disruptors & Dominators as the “Anthropic IPO Loophole,” points to a likely stock. We trace the Anthropic and IPO promises back to the filings.
Keith Kohl’s Energy Investor promotion from Angel Publishing’s Outsider Club, The Nuclear Reckoning, pitches five nuclear stocks. We identify the lead and test the shortage story.
Ian King of Banyan Hill is promoting The Musk Master Key in Strategic Fortunes; here’s the company the clues point to and where the filings push back.